Navigation Links
IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Date:12/10/2012

NEW YORK, Dec. 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Dr. Harry Fisch has joined the Board of Scientific Advisors and will head up the new Urology Department at IntelliCell. 

IntelliCell's Chairman and CEO, Dr. Steven Victor stated, "Our Company is very pleased to announce today that Dr. Fisch is joining our Advisory Board and will be the Director of Urology for IntelliCell.  He is a pioneering surgeon and respected on the national stage for his work on microsurgical techniques.  I am looking forward to working with him as we expand the potential benefits of Regenerative Medicine into the practice of urology."

Said Dr. Fisch, "I believe that the promise of Regenerative Medicine for patients suffering from a number of urological disorders including erectile dysfunction may become an important part in the practice of medicine.  This is an exciting time in medicine and I am looking forward to working with cutting edge technologies like IntelliCell's and improving the clinical outcomes of my patients."   

About IntelliCell BioSciences

IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs.  The Company has several patent-pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells.  The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes.  IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics.  The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center. 

About Dr. Fisch

Dr. Harry Fisch is Clinical Professor of Urology and Reproductive Medicine at Weill-Cornell Medical College/New York Presbyterian Hospital, and is a board-certified urologist and microsurgeon who is also one of the nation's leaders in the diagnosis and treatment of Men's health issues as well as sexuality and fertility problems in couples. Internationally renowned, he has pioneered microsurgical techniques for disorders associated with male infertility such as vasectomy reversal and repair of varicoceles. He has been frequently cited in a variety of publications, including USA Today, The New York Times, and The Washington Post and has appeared on television's 60 Minutes, 20/20, CNN and Today, among many others. He has been named to the "Best Doctors in America" and "New York Magazine Top Doctor" for the past 9 years.

Dr. Fisch has written two engaging and critically acclaimed books on the subject of male reproduction and sexuality.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email:  rsexauer@intellicellbiosciences.com 
(646) 576-8706  


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
2. IntelliCell BioSciences Expands Management Team
3. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
4. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
5. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
6. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
7. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
8. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... FireflySci Inc. is a go-getter type of company that ... accounted to two main factors. The first is the amazing customer service that ... FireflySci products all around the world. , 2016 was a tremendous sales year for ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, Inc., ... the formation of an Executive Committee that will guide ... John Cucci , a 15-year veteran ... Director of Business Development to Chief Sales Officer ... Cucci served in senior sales leadership roles at several ...
(Date:1/18/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, will feature data from two clinical studies ... ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in ... Napabucasin is an orally-administered investigational agent designed to inhibit ... stem cells (CSCs) possess the property of stemness – ...
(Date:1/18/2017)... Malden, MA (PRWEB) , ... January 18, 2017 ... ... announced today that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation ... Medical Center in Valley Stream, NY. The procedure was an anterior cervical discectomy ...
Breaking Biology Technology:
(Date:1/4/2017)... -- For the thousands of attendees at this year,s International Consumer Electronics Show ... biometric measurement devices and services, will be featuring its new line of ... Medical,s special CES Exhibit Suite , the new upper arm and ... WellnessConnected product platform.  Continue ... ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   ... data sensor technology, and STMicroelectronics (NYSE: ... spectrum of electronics applications, announced today the launch ... kit for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, ...
Breaking Biology News(10 mins):